Human-caused Phenomenon or Process
Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial
Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment
FDA, CDC call for pause of chikungunya shot rollout in older adults
Ixchiq vaccine, chikungunya, safety concerns, older adults, FDA, CDC, pause recommendation, adverse events
Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership
gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety
Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC
Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety
Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss
orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Mallinckrodt, Endo set for $6.7B merger
pharmaceutical merger, opioid litigation, generics, injectables, synergies
Mallinckrodt and Endo Announce $6.7 Billion Merger to Create Diversified Pharmaceutical Leader
Pharmaceutical merger, Mallinckrodt, Endo, opioid litigation, generics, branded drugs, synergies
Pharmaceutical Giants Mallinckrodt and Endo Explore $7 Billion Merger
Pharmaceutical merger, Mallinckrodt, Endo, $7 billion deal, Specialty pharmaceutical companies, Post-bankruptcy consolidation, Opioid crisis fallout